Clinical Scorecard: Clarifying the Inpatient and Residential Benzodiazepine Tapering Guidelines from ASAM

At a Glance

Key Highlights

• Inpatient admission recommended for imminent risk of harm or complex tapering needs (source needed)
• Tapering often requires a transition from inpatient to outpatient care (source needed)
• Lack of clear definition for 'severe or complicated withdrawal' in guidelines (source needed)
• Phenobarbital tapers allowed but with limited guidance on patient selection (source needed)
• Protracted withdrawal symptoms may persist post-inpatient detoxification (source needed)

Guideline-Based Recommendations

Diagnosis

• Clarify criteria for benzodiazepine use disorder (BUD) diagnosis for insurance coverage (source needed)

Management

• Inpatient care primarily for stabilization; outpatient tapering often necessary (source needed)
• Define 'severe or complicated withdrawal' with specific clinical criteria (source needed)
• Specify when to use phenobarbital tapers over standard benzodiazepine tapers (source needed)

Monitoring & Follow-up

• Regular outpatient monitoring required post-discontinuation to manage withdrawal symptoms (source needed)

Risks

• Potential for misdiagnosis and inappropriate medication changes without adequate follow-up (source needed)

Patient & Prescribing Data

Patients undergoing benzodiazepine tapering, including those with complex needs

Individualized treatment plans are essential due to variability in patient needs

Clinical Best Practices

• Ensure clear communication about the role of inpatient care in the tapering process (source needed)
• Monitor patients closely for protracted withdrawal symptoms post-discharge (source needed)
• Educate providers on the limitations of phenobarbital tapers and facility availability (source needed)

Related Resources & Content

• ASAM Joint Clinical Practice Guidelines on Benzodiazepine Tapering